Pre‐ and post‐treatment blood‐based genomic landscape of patients with ROS1 or NTRK fusion‐positive solid tumours treated with entrectinib
Sign Up to like & getrecommendations! Published in 2022 at "Molecular Oncology"
DOI: 10.1002/1878-0261.13214
Abstract: Genomic tumour profiling informs targeted treatment options. Entrectinib is a tyrosine kinase inhibitor with efficacy in NTRK fusion‐positive (‐fp) solid tumours and ROS1‐fp non‐small cell lung cancer. FoundationOne® Liquid CDx (F1L CDx), a non‐invasive in vitro… read more here.
Keywords: positive solid; fusion positive; ntrk fusion; treatment ... See more keywords
NUTM1‐fusion positive malignant neoplasms of the genitourinary tract: A report of six cases highlighting involvement of unusual anatomic locations and histologic heterogeneity
Sign Up to like & getrecommendations! Published in 2022 at "Genes"
DOI: 10.1002/gcc.23046
Abstract: Tumors with NUTM1 fusions occur predominantly in the thoracic cavity and head and neck region. However, recent literature expanded the location of NUTM1‐translocated malignancy to soft tissue, brain, and visceral organs. In this study, we… read more here.
Keywords: fusion; nutm1 fusion; bladder; kidney ... See more keywords
RREB1::MRTFB fusion‐positive extra‐glossal mesenchymal neoplasms: A series of five cases expanding their anatomic distribution and highlighting significant morphological and phenotypic diversity
Sign Up to like & getrecommendations! Published in 2022 at "Genes"
DOI: 10.1002/gcc.23082
Abstract: The RREB1::MRTFB (former RREB1::MKL2) fusion characterizes ectomesenchymal chondromyxoid tumors (EMCMT) of the tongue. Only five molecularly confirmed extra‐glossal EMCMT cases have been reported recently; all occurring at head and neck or mediastinal sites. We herein… read more here.
Keywords: extra glossal; fusion; mrtfb fusion; fusion positive ... See more keywords
ALK‐rearranged Mesenchymal Neoplasms: A Report of 9 cases Further Expanding the Clinicopathologic Spectrum of Emerging Kinase Fusion Positive Group of Tumors
Sign Up to like & getrecommendations! Published in 2022 at "Genes"
DOI: 10.1002/gcc.23097
Abstract: Anaplastic lymphoma kinase (ALK) fusions are oncogenic drivers in diverse cancer types. Although well established in inflammatory myofibroblastic tumor (IMT) and epithelioid fibrous histiocytoma (EFH), ALK rearrangements also occur in the emerging family of kinase… read more here.
Keywords: rearranged mesenchymal; mesenchymal neoplasms; alk rearranged; fusion positive ... See more keywords
Therapeutic Advances in the Management of Patients with Advanced RET Fusion-Positive Non-Small Cell Lung Cancer
Sign Up to like & getrecommendations! Published in 2021 at "Current Treatment Options in Oncology"
DOI: 10.1007/s11864-021-00867-8
Abstract: Screening for activating driver gene alterations at the time of diagnosis is the standard of care for advanced non-small cell lung cancer (NSCLC). Activating RET fusions are identified in approximately 1–2% of NSCLCs and have… read more here.
Keywords: ret fusion; cell lung; non small; fusion positive ... See more keywords
NTRK fusion-positive cancers and TRK inhibitor therapy
Sign Up to like & getrecommendations! Published in 2018 at "Nature Reviews Clinical Oncology"
DOI: 10.1038/s41571-018-0113-0
Abstract: NTRK gene fusions involving either NTRK1, NTRK2 or NTRK3 (encoding the neurotrophin receptors TRKA, TRKB and TRKC, respectively) are oncogenic drivers of various adult and paediatric tumour types. These fusions can be detected in the… read more here.
Keywords: ntrk fusion; trk inhibitors; trk; fusion ... See more keywords
Selpercatinib in RET-fusion positive metastatic non-small cell lung cancer: achievements and gray areas
Sign Up to like & getrecommendations! Published in 2022 at "Expert Review of Anticancer Therapy"
DOI: 10.1080/14737140.2022.2093190
Abstract: ABSTRACT Introduction Selpercatinib is a RET selective tyrosine kinase inhibitor with nanomolar potency against diverse RET alterations, including fusions, activating point mutations, and acquired resistance mutations. Rearranged during transfection (RET) gene is a validated target… read more here.
Keywords: non small; selpercatinib ret; fusion positive; small cell ... See more keywords
HGG-01. ENTRECTINIB IN RECURRENT OR REFRACTORY SOLID TUMORS INCLUDING PRIMARY CNS TUMORS: UPDATED DATA IN CHILDREN AND ADOLESCENTS
Sign Up to like & getrecommendations! Published in 2020 at "Neuro-Oncology"
DOI: 10.1093/neuonc/noaa222.293
Abstract: Abstract STARTRK-NG (phase 1/2) is evaluating entrectinib, a CNS-penetrant oral, TRK/ROS1/ALK tyrosine kinase inhibitor, in patients read more here.
Keywords: solid tumors; cns tumors; cns; ros1 ... See more keywords
S100 and Pan-Trk Staining to Report NTRK Fusion-Positive Uterine Sarcoma: Proceedings of the ISGyP Companion Society Session at the 2020 USCAP Annual Meeting.
Sign Up to like & getrecommendations! Published in 2021 at "International Journal of Gynecological Pathology"
DOI: 10.1097/pgp.0000000000000702
Abstract: NTRK fusion-positive uterine sarcoma is a recently recognized mesenchymal tumor that is defined by its morphologic resemblance to soft tissue fibrosarcoma, NTRK gene rearrangements, and potential response to Trk inhibition. Reported lesions affect premenopausal women… read more here.
Keywords: fusion positive; uterine sarcoma; pan trk; fusion ... See more keywords
Abstract CT131: Entrectinib inNTRK-fusion positive (NTRK-FP) non-small cell lung cancer (NSCLC): Integrated analysis of patients enrolled in three trials (STARTRK-2, STARTRK-1 and ALKA-372-001)
Sign Up to like & getrecommendations! Published in 2019 at "Clinical Trials"
DOI: 10.1158/1538-7445.am2019-ct131
Abstract: Background Gene fusions involving NTRK (neurotrophic receptor tyrosine kinase) genes result in the expression of chimeric TRK proteins with uncontrolled kinase activity, leading to oncogenic transformation and unrestrained cancer cell proliferation, which confers oncogenic potential… read more here.
Keywords: fusion positive; cancer; cell; ntrk ... See more keywords
Abstract CT011: Efficacy and safety of selpercatinib in RET fusion-positive cancers other than lung or thyroid cancers
Sign Up to like & getrecommendations! Published in 2021 at "Clinical Trials"
DOI: 10.1158/1538-7445.am2021-ct011
Abstract: Introduction: Selpercatinib, a first-in-class highly selective and potent RET kinase inhibitor, is approved in multiple countries for the treatment of RET fusion-positive lung or thyroid cancers. RET fusions are also implicated in the pathogenesis of… read more here.
Keywords: fusion positive; thyroid cancers; non; ret fusion ... See more keywords